People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology, Healthtech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Talaris Therapeutics, Inc. | — | Biotechnology | Series D+ | $115.0M | $4.4B | 2020 |
| Boulder Care, Inc. | — | Healthtech | Series B | $81.2M | $249.6M | 2022 |
| Platelet BioGenesis, Inc. | — | Other | Series B | $72.9M | $426.7M | 2017 |
| Amphivena Therapeutics, Inc. | — | Biotechnology | Series B | $65.2M | $1.5B | 2018 |
| Dualitas Therapeutics, Inc. | — | Biotechnology | Series B | $32.6M | $150.2M | 2025 |
Mark McDade at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark McDade on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Murray | 2 | 5 |
| Michael Ross | 1 | 18 |
| Josh Kopelman | 1 | 14 |
| Luke Evnin | 1 | 12 |
| David ibnAle | 1 | 7 |
| ERIC MOESSINGER | 1 | 6 |
| Geoff MacKay | 1 | 5 |
| Scott Requadt | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Peter Finn | 1 | 5 |
| Frank Muhlenbeck | 1 | 4 |
| Phil Gutry | 1 | 4 |
| Thomas Hudson | 1 | 4 |
| Jordan Nof | 1 | 4 |
| Frank Ingari | 1 | 3 |
| Nick Galakatos | 1 | 3 |
| Chidozie Ugwumba | 1 | 3 |
| Francois Nader | 1 | 3 |
| Nikola Trbovic | 1 | 3 |
| Steve Altschuler | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.